Evolution Of Immunogenicity Assessment: Moving Into The Data Rich Era

This webinar underscores the significance of immunogenicity risk assessment within the developability package for biologics. Integrating such assessments into lead candidate selection prior to clinical trials minimizes development risks and strengthens Investigational New Drug (IND) applications. These assays are evolving to become more data-rich, and in this webinar, we provide an overview of current practices and future directions.

We present a novel flow cytometry-based assay for sensitive T cell proliferation analysis which utilizes an EdU readout, allowing for multiplexing with customizable activation markers and cytokine level assessment. This approach offers a more comprehensive understanding of immunogenicity risk. Additionally, we explore the potential for "flipping" immunogenicity risk assessment to support vaccine development by examining a case study that showcases the application of MHC class I assays to facilitate epitope identification.

View the webinar below and learn how immunogenicity testing as part of developability can help to de-risk drug development progress, how the evolution of assays can inform better decision-making, and how immunogenicity risk assessment can aid vaccine development.